[go: up one dir, main page]

MA33607B1 - Molécules de liaison bispécifiques pour une thérapie anti-angiogénique - Google Patents

Molécules de liaison bispécifiques pour une thérapie anti-angiogénique

Info

Publication number
MA33607B1
MA33607B1 MA34720A MA34720A MA33607B1 MA 33607 B1 MA33607 B1 MA 33607B1 MA 34720 A MA34720 A MA 34720A MA 34720 A MA34720 A MA 34720A MA 33607 B1 MA33607 B1 MA 33607B1
Authority
MA
Morocco
Prior art keywords
binding molecules
bispecific binding
relates
angiogenic therapy
dll4
Prior art date
Application number
MA34720A
Other languages
Arabic (ar)
English (en)
Inventor
Eric Borges
Andreas Gschwind
Joachim Boucneau
Tavernier Evelyn De
Joost Kolkman
Pascal Merchiers
Hoorick Diane Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33607(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33607B1 publication Critical patent/MA33607B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des molécules de liaison bispécifiques, en particulier des domaines variables uniques d'immunoglobuline tels que des vhh et des anticorps à domaine comprenant un composant de liaison à vegf et un composant de liaison à dll4 dans une molécule. L'invention concerne également des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies qui sont associées à des effets à médiation par vegf et dll4 sur l'angiogenèse. L'invention concerne également des acides nucléiques codant pour les molécules de liaison bispécifiques, des cellules hôtes et des procédés pour les préparer.
MA34720A 2009-10-02 2012-03-26 Molécules de liaison bispécifiques pour une thérapie anti-angiogénique MA33607B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172137 2009-10-02
EP10175316 2010-09-03
PCT/EP2010/064695 WO2011039370A1 (fr) 2009-10-02 2010-10-01 Molécules de liaison bispécifiques pour une thérapie anti-angiogénique

Publications (1)

Publication Number Publication Date
MA33607B1 true MA33607B1 (fr) 2012-09-01

Family

ID=43431796

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34720A MA33607B1 (fr) 2009-10-02 2012-03-26 Molécules de liaison bispécifiques pour une thérapie anti-angiogénique

Country Status (24)

Country Link
US (2) US20110172398A1 (fr)
EP (1) EP2483314A1 (fr)
JP (2) JP5833009B2 (fr)
KR (1) KR20120101375A (fr)
CN (2) CN105037542A (fr)
AP (1) AP2012006188A0 (fr)
AR (1) AR078515A1 (fr)
AU (1) AU2010302589A1 (fr)
BR (1) BR112012007239A2 (fr)
CA (1) CA2775422A1 (fr)
CL (1) CL2012000826A1 (fr)
EA (1) EA201200548A1 (fr)
EC (1) ECSP12011835A (fr)
IL (1) IL218542A0 (fr)
IN (1) IN2012DN02752A (fr)
MA (1) MA33607B1 (fr)
MX (1) MX2012003897A (fr)
NZ (2) NZ626302A (fr)
PE (1) PE20121024A1 (fr)
PH (1) PH12012500525A1 (fr)
TN (1) TN2012000145A1 (fr)
TW (1) TW201124533A (fr)
UY (1) UY32920A (fr)
WO (1) WO2011039370A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750124B2 (en) * 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP3243835B1 (fr) 2009-02-11 2024-04-10 Albumedix Ltd Variants et conjuges de l'albumine
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
WO2011025964A2 (fr) 2009-08-29 2011-03-03 Abbott Laboratories Protéines thérapeutiques se liant à dll4
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
ES2700230T3 (es) 2009-10-30 2019-02-14 Albumedix Ltd Variantes de albúmina
UA112743C2 (uk) 2010-03-02 2016-10-25 Еббві Інк. Терапевтичний dll4-зв'язувальний білок
PE20130207A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
EA201291181A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
WO2012010550A1 (fr) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Méthode d'identification d'un patient présentant une probabilité accrue de répondre à un traitement anticancéreux
KR20130126576A (ko) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012068098A1 (fr) * 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Méthodes de traitement du cancer par des antagonistes de dll4
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AU2015268749B2 (en) * 2011-09-23 2017-05-25 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
LT3485903T (lt) * 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
AR088633A1 (es) 2011-11-04 2014-06-25 Novartis Ag Constructos extensores de vida media de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6)
WO2013075066A2 (fr) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
MX2015003894A (es) * 2012-09-28 2015-07-17 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf.
EP2900261A1 (fr) * 2012-09-28 2015-08-05 Boehringer Ingelheim International GmbH Combinaisons pharmaceutiques comprenant des liants doubles angiopoïétine-2/dll4 et des agents anti-vegf-r
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
EP3466973A1 (fr) * 2012-11-01 2019-04-10 AbbVie Inc. Formulations de protéine immunoglobuline à domaine variable double stable
EP2917233A1 (fr) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Variants d'albumine
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US10184010B2 (en) 2013-07-09 2019-01-22 Ablbio Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof
US11185583B2 (en) * 2014-02-11 2021-11-30 Albany Medical College Multi-functional mucosal vaccine platform
BR112016023011A2 (pt) * 2014-04-04 2017-10-17 Oncomed Pharm Inc tratamento de câncer gástrico
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
EP3212233B1 (fr) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016192613A1 (fr) * 2015-06-01 2016-12-08 中山大学 Anticorps bivalent comportant un fragment de liaison à l'antigène à domaine unique fusionné à un fragment fab classique
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017029407A1 (fr) 2015-08-20 2017-02-23 Albumedix A/S Variants de l'albumine et leurs conjugués
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CA3009644A1 (fr) * 2015-12-04 2017-06-08 The Regents Of The University Of California Nouveaux anticorps pour le traitement de cancers
EP3453759B1 (fr) * 2016-01-29 2023-08-30 Kyoto University Promoteur de production plaquettaire et procédé de production plaquettaire au moyen de celui-ci
IL309890A (en) * 2017-01-30 2024-03-01 Alexion Pharma Inc Monovalent anti-properdin antibodies and antibody fragments
CN112004826B (zh) * 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
CN111995686B (zh) * 2019-05-27 2022-06-14 兰州大学 一种具有抗血管生成活性的药物及其制备方法
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
WO2022057888A1 (fr) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène bispécifique se liant spécifiquement au vegf et à l'ang-2
CN112535738B (zh) * 2020-12-04 2022-09-09 中国科学技术大学 奥沙利铂偶联物及其制备方法和应用
CA3207763A1 (fr) * 2021-02-10 2022-08-18 Zongda Wang Anticorps anti-vegf et son utilisation
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
WO2023092327A1 (fr) * 2021-11-24 2023-06-01 Linno Pharmaceuticals Inc. Protéine de liaison au vegf et son utilisation
CN116063469B (zh) * 2022-08-29 2023-09-22 中山大学 一种寨卡病毒中和性纳米抗体及其制备方法与应用
CN119866346A (zh) * 2022-09-14 2025-04-22 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
JPWO2024106394A1 (fr) 2022-11-14 2024-05-23
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用
CN117860786B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
WO2025212751A1 (fr) * 2024-04-02 2025-10-09 Therini Bio, Inc. Protéines de liaison à l'antigène multi-spécifiques se liant au domaine yc de la fibrine humaine ou au domaine yc du fibrinogène et au facteur de croissance endothéliale vasculaire et procédés d'utilisation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589107B1 (fr) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulines dépourvus de chaînes légères
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1803730A1 (fr) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Proteines de fusion d'albumine
IL156955A0 (en) 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
WO2003002609A2 (fr) 2001-06-28 2003-01-09 Domantis Limited Ligand
EP1463752A4 (fr) 2001-12-21 2005-07-13 Human Genome Sciences Inc Proteines de fusion d'albumine
EP2258392A1 (fr) 2002-11-08 2010-12-08 Ablynx N.V. Procédé d'administration de polypeptides thérapeutiques
KR101103218B1 (ko) 2002-11-08 2012-01-05 아블린쓰 엔.브이. 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
CA2529819A1 (fr) 2003-06-30 2004-09-23 Domantis Limited Anticorps a domaine unique pegyles
WO2005040219A1 (fr) * 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications
EP1687338B1 (fr) 2003-11-07 2010-10-20 Ablynx N.V. Anticorps a domaine unique vhh de camelidae diriges contre le recepteur de facteur de croissance epidermique et utilisations de ceux-ci
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
HUE039846T2 (hu) * 2005-05-20 2019-02-28 Ablynx Nv Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DK1962895T3 (da) 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
CN101490084A (zh) * 2006-06-06 2009-07-22 健泰科生物技术公司 抗dll4抗体及其使用方法
US20080014196A1 (en) * 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
MX2008015541A (es) * 2006-06-06 2008-12-18 Genentech Inc Anticuerpos anti-dll4 y metodos que los usan.
JP5529536B2 (ja) * 2006-08-07 2014-06-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 虚血性障害又は血管不全の治療におけるＤｌｌ４アンタゴニストの使用
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20080132451A1 (en) * 2006-12-01 2008-06-05 Alcon Manufacturing Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CA2678218A1 (fr) * 2007-02-21 2008-08-28 Ablynx N.V. Sequences d'acides amines dirigees contre le facteur de croissance de l'endothelium vasculaire et polypeptides comprenant ces sequences, pour le traitement de troubles et de maladies se caracterisant par une angiogenese pathologique ou une neovascularisation
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2260058A2 (fr) * 2008-04-07 2010-12-15 Ablynx N.V. Séquences d acides aminés dirigées contre les voies notch et leurs utilisations
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010129304A2 (fr) * 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis

Also Published As

Publication number Publication date
US20140120095A1 (en) 2014-05-01
EA201200548A1 (ru) 2012-12-28
NZ598956A (en) 2014-07-25
UY32920A (es) 2011-04-29
KR20120101375A (ko) 2012-09-13
AP2012006188A0 (en) 2012-04-30
WO2011039370A1 (fr) 2011-04-07
JP2016026207A (ja) 2016-02-12
CN105037542A (zh) 2015-11-11
JP5833009B2 (ja) 2015-12-16
CA2775422A1 (fr) 2011-04-07
US20110172398A1 (en) 2011-07-14
AU2010302589A1 (en) 2012-04-19
CN102639566A (zh) 2012-08-15
IN2012DN02752A (fr) 2015-09-18
CL2012000826A1 (es) 2012-10-19
BR112012007239A2 (pt) 2019-09-24
EP2483314A1 (fr) 2012-08-08
IL218542A0 (en) 2012-05-31
JP2013506411A (ja) 2013-02-28
PH12012500525A1 (en) 2012-11-26
ECSP12011835A (es) 2012-06-29
CN102639566B (zh) 2015-07-22
TW201124533A (en) 2011-07-16
MX2012003897A (es) 2012-05-08
NZ626302A (en) 2015-09-25
TN2012000145A1 (en) 2013-09-19
AR078515A1 (es) 2011-11-16
PE20121024A1 (es) 2012-08-10

Similar Documents

Publication Publication Date Title
MA33607B1 (fr) Molécules de liaison bispécifiques pour une thérapie anti-angiogénique
MA33609B1 (fr) Molecules de liaison a dll4
MA34979B1 (fr) Molecules de liaisonbispecifiques se liant a vegf et ang2
MA35233B1 (fr) Molecules de liaison bispecifiques se liant à dii4 et ang2
Kim et al. GDF-15 secreted from human umbilical cord blood mesenchymal stem cells delivered through the cerebrospinal fluid promotes hippocampal neurogenesis and synaptic activity in an Alzheimer's disease model
Couturier et al. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA56289A (fr) Mutéines d'interleukine-21 et méthodes de traitement
MX2009002418A (es) Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MX345226B (es) Formulaciones de moleculas de union a antigeno de dominio sencillo.
CA2820681C (fr) Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer
MX350355B (es) Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
EA201000910A1 (ru) Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
MA35437B1 (fr) Proteines de fusion pour le traitement de troubles du metabolisme
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA29427B1 (fr) Antagonistes et leurs methodes d'utilisation
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
MA38930A1 (fr) Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)